Skip to main content

Table 2 Univariate survival analysis based on KRAS status or SLFN11 expression status

From: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

   

DFS

OS

  

No.

3y-DFS(%)

HR(95 %CI)

P

5y-OS

HR(95 %CI)

P

Patients with KRAS wt

        
 

SLFN11high

23

91.3

0.347(0.083–1.449)

0.147

100.0

 

0.05

 

SLFN11low

130

75.8

1

 

83.3

  

Patients with KRAS mt

        
 

SLFN11high

12

72.9

1.424(0.391–5.188)

0.592

80.2

1.348(0.279–6.508)

0.71

 

SLFN11low

51

83.9

1

 

81.9

1

 

Patients with SLFN11high

        
 

KRAS wt

23

91.3

1

0.207

100.0

 

0.06

 

KRAS mt

12

72.9

3.167(0.528–18.979)

 

80.2

  

Patients with SLFN11low

        
 

KRAS wt

130

75.8

1

0.511

80.5

 

0.503

 

KRAS mt

51

83.9

0.787(0.386–1.607)

 

81.9

0.749(0.321–1.746)